A Real World Study Investigating the Long Term Efficacy and Safety of Nimotuzumab with Concurrent Chemoradiotherapy (CCRT) in Patients with Unresectable Locally Advanced Head and Neck Cancer
Phase of Trial: Phase IV
Latest Information Update: 27 Jun 2018
Price : $35 *
At a glance
- Drugs Nimotuzumab (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- 27 Jun 2018 New trial record
- 05 Jun 2018 According to results presented at the 54th Annual Meeting of the American Society of Clinical Oncology, patients were included in this study between October 2010 to November 2016.
- 05 Jun 2018 Results presented at the 54th Annual Meeting of the American Society of Clinical Oncology.